Business Description
Context Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US21077P1084
Total Employee Number:
15Description
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 193.37 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.5 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 30.3 | |||||
3-Year Book Growth Rate | -32.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -11.03 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.28 | |||||
9-Day RSI | 36.04 | |||||
14-Day RSI | 32.23 | |||||
3-1 Month Momentum % | -76.89 | |||||
6-1 Month Momentum % | -75.83 | |||||
12-1 Month Momentum % | -31.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.96 | |||||
Quick Ratio | 8.96 | |||||
Cash Ratio | 8.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -79.2 | |||||
Shareholder Yield % | 0.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -55.97 | |||||
ROA % | -52.01 | |||||
ROIC % | -2915.52 | |||||
3-Year ROIIC % | -3795.41 | |||||
ROC (Joel Greenblatt) % | -8109.77 | |||||
ROCE % | -60.5 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.04 | |||||
Price-to-Tangible-Book | 1.04 | |||||
EV-to-Forward-EBITDA | -1.35 | |||||
| Price-to-Net-Current-Asset-Value | 1.05 | |||||
| Price-to-Net-Cash | 1.14 | |||||
FCF Yield % | -60.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Context Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.42 | ||
| Beta | 0.185 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.36 | ||
| Volatility % | 125.45 | ||
| 14-Day RSI | 32.23 | ||
| 14-Day ATR ($) | 0.076052 | ||
| 20-Day SMA ($) | 0.61834 | ||
| 12-1 Month Momentum % | -31.76 | ||
| 52-Week Range ($) | 0.5451 - 3.62 | ||
| Shares Outstanding (Mil) | 91.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Context Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Context Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 99 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 8 days | ||
| General meeting for 2026 | 2026-06-24 08:00 | 0.65 (+8.44%) | ||
| Context Therapeutics Inc Jefferies Global Healthcare Conference | 2026-06-03 07:35 | 2.42 (-12.64%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 2.44 (+4.27%) | ||
| Annual report for 2025 | 2026-03-23 | 2.88 (-2.70%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 2.88 (-2.70%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 09:20 | 2.92 (+1.39%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 10:30 | 2.29 (+4.09%) | ||
| Guidance call for 2025 | 2025-11-12 10:00 | 1.19 (-0.83%) |
Show
Entries
Context Therapeutics Inc Frequently Asked Questions
What is Context Therapeutics Inc(CNTX)'s stock price today?
The current price of CNTX is $0.59. The 52 week high of CNTX is $3.62 and 52 week low is $0.55.
When is next earnings date of Context Therapeutics Inc(CNTX)?
The next earnings date of Context Therapeutics Inc(CNTX) is 2026-08-06 Est..
Does Context Therapeutics Inc(CNTX) pay dividends? If so, how much?
Context Therapeutics Inc(CNTX) does not pay dividend.
Guru Commentaries on NAS:CNTX
No articles.
Press Release
Articles on Context Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers